Ignite Creation Date:
2025-12-24 @ 2:43 PM
Ignite Modification Date:
2026-01-01 @ 2:01 PM
Study NCT ID:
NCT00742859
Status:
COMPLETED
Last Update Posted:
2023-08-07
First Post:
2008-08-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Sponsor:
Portola Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-10
Start Date Type:
None
Primary Completion Date:
2009-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-11
Completion Date Type:
ACTUAL
First Submit Date:
2008-08-26
First Submit QC Date:
None
Study First Post Date:
2008-08-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-07-20
Results First Submit QC Date:
None
Results First Post Date:
2017-09-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2016-12-02
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2023-08-03
Last Update Post Date:
2023-08-07
Last Update Post Date Type:
ACTUAL